🇺🇸

US SEC Filing Intelligence

· daily

US IPO Pipeline SEC S-1 Filings — August 24, 2026

The August 24, 2026 IPO pipeline is dominated by two blank-check companies (Essential Minerals Acquisition Corp and Live Oak Acquisition Corp. VI) seeking a combined $350 million, alongside three resale registrations from cash-strapped issuers (NEXTNRG, Polar Power, and Serina Therapeutics) and one de-SPAC merger filing (OHB Pediatrics Ltd.). A critical portfolio-level pattern is the extreme financial distress among operating companies: NEXTNRG has only ~$4.5M cash (funding through Dec 1, 2026) and negative working capital, while Polar Power reports just ~$0.1M in stockholders' equity against a Nasdaq minimum of $2.5M. The blank-check IPOs offer a stark contrast with zero-operating-risk structures but carry significant dilution risks for public shareholders. No period-over-period comparisons were available as all filings are initial registrations without historical financial performance data. The most actionable insight is the imminent liquidity crisis at NEXTNRG and Polar Power, which could force distressed asset sales or reverse stock splits, creating potential short-term trading opportunities.

6 high priority 6 total filings
· daily

US Executive Officer Management Changes SEC — August 24, 2026

The August 24, 2026 executive and director change filings reveal a portfolio experiencing significant leadership turnover, with a notable undercurrent of governance risk and financial distress. Across 25 filings, we see a pattern of CFO appointments in companies with turnaround or restructuring narratives (Hormel, Ecovyst, USBC), while in the biotech sector, multiple small-cap firms are bolstering boards with seasoned dealmakers (ANI, FibroBiologics). The most critical developments include a CEO's paid administrative leave due to a governmental investigation at Grand Canyon Education, two board resignations reducing governance oversight at Allurion Technologies, and a high-risk CFO appointment at USBC who is a named defendant in multiple SVB-related litigations. Conversely, the CEO succession at Extra Space Storage and the new CCO role at Trex signal strategic depth in large-cap real estate and building products. While many filings lack period-over-period financial data, several disclose forward-looking statements, including reaffirmed guidance (Azenta), merger-completion bonuses (Twin Vee), and aggressive revenue targets (QXO). Insider activity is sparse, but the compensation structures for new executives, including sign-on bonuses and long-term incentives, provide insights into company alignment strategies. The overarching themes are high governance turnover, a search for operational and financial stability, and a distinct divide between well-capitalized companies executing successions and distressed firms facing existential threats.

25 high priority 25 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — August 24, 2026

The sole filing for the USA Bankruptcy & Insolvency stream on this quiet session is a highly material 8-K from Bubblr Inc. (BBLR), revealing that a U.S. District Court has appointed a Receiver for the company. This receivership represents a severe adverse regulatory action, effectively removing management's control and signaling acute financial distress. The filing provides no financial metrics, period-over-period comparisons, or forward-looking guidance, which is typical for such a sudden and extreme corporate event. The appointment of a Receiver is a precursor to potential liquidation or a forced restructuring, making this the single most critical development in the stream. The lack of any other filings underscores a very quiet session, with this event dominating the bankruptcy and insolvency landscape for the day.

1 high priority 1 total filings
· daily

US Corporate Board Director Changes SEC Filings — August 24, 2026

This edition of the USA Board Room Changes digest covers 25 filings, with a significant concentration of leadership changes spanning routine appointments, governance shake-ups, and a notable CEO succession. A key pattern emerging is the frequency of CFO transitions (5 filings) and the simultaneous departure/reduction of board seats (Allurion Technologies, Greenlane Holdings, MAKO Medical, Malibu Boats), which signals potential instability or strategic pivots in select firms. While most changes were neutral in sentiment, several carry actionable intelligence: Grand Canyon Education’s CFO leave amid an insider trading investigation is a major red flag, and USBC’s appointment of a CFO facing multiple FDIC litigations introduces high governance risk. On the opportunity side, Extra Space Storage’s well-planned CEO succession and QXO’s appointment of a seasoned President/COO to drive M&A-led growth appear positive catalysts. Period-over-period data was sparse in these event-driven filings, limiting trend analysis, but forward-looking statements (e.g., QXO’s $50B revenue target) and insider activity (e.g., Polar Power’s new board to address going-concern) provided depth. Overall, investors should focus on governance quality signals, as board composition is a leading indicator of strategic direction and risk management.

25 high priority 25 total filings
· daily

USA Insider Trading Pulse — August 24, 2026

This USA Insider Trading Pulse digest covers 50 filings from August 24, 2026, revealing a cautious to bearish tone among corporate insiders, with 20 distinct open-market sales events totaling ~$21.8M versus 9 open-market purchases for ~$5.5M, a notable 4:1 sell-to-buy dollar ratio. The most significant transactions include a Director at DoorDash selling $16.3M via a 10b5-1 plan, an EVP at Packaging Corp of America selling $3M, and the Alibaba CEO buying $4.98M of stock, which stands out as a high-conviction vote of confidence. A clear cluster of insider selling is observed at Procter & Gamble, where four senior executives, including the CFO, collectively sold ~$1.53M, potentially signaling concerns ahead of a future earnings report. Tax-withholding-for-vesting transactions provide limited directional insight, but their volume at companies like LiveRamp and NIQ Global Intelligence suggests significant equity compensation vesting. Key themes include concentrated insider selling at large-cap consumer staples (P&G) and tech-enabled logistics (DoorDash), contrasted with targeted insider buying at select technology and financial names, suggesting bifurcated sector conviction. The data does not contain direct forward-looking guidance, but insider activity patterns serve as a leading indicator for upcoming earnings and strategic shifts.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — August 24, 2026

The August 24, 2026, M&A and takeover filings reveal a bifurcated SPAC landscape: while two blank-check companies (Roman DBDR, Pantages Capital) face Nasdaq delisting risks due to non-compliance with listing standards, two others (Integrated Wellness, International Media) are actively pursuing or extending deadlines for business combinations. The most material event is the completed acquisition of RE/MAX Holdings by The Real Brokerage Inc., a definitive deal with a clear valuation structure and immediate delisting, marking a significant consolidation in the real estate brokerage sector. Martin Marietta Materials' strategic bolt-on acquisition of Lhoist North America adds over 2 billion tons of limestone reserves, reinforcing its specialty materials platform without disclosed financial terms. In contrast, the complete wind-down of the Hashdex Bitcoin ETF (Tidal Commodities Trust I) represents a total liquidation event with no ongoing operations, signaling a negative sentiment for the crypto-ETF space. Period-over-period comparisons are largely absent from these event-driven filings, but the forward-looking data (compliance deadlines, extension dates, merger completion) provides a clear catalyst calendar. Insider activity is limited, though the appointment of Binson Lau as Co-CEO of Integrated Wellness, who is also CEO of the merger target Btab, signals strong alignment with deal completion. Capital allocation is not a primary theme, but the RE/MAX deal structure (cash/stock election with proration) offers a unique arbitrage opportunity. Overall, the digest highlights a market where SPACs are under regulatory pressure, traditional M&A is value-accretive, and crypto-linked vehicles are being wound down.

7 high priority 7 total filings
· monthly

US Pre-Market SEC Filings Roundup — August 24, 2026

This pre-market digest covers 50 overnight SEC filings from August 23-24, 2026, revealing a market dominated by significant capital events and strategic shifts. The most impactful themes include a wave of going-private and M&A transactions (Utz Brands at a 91% premium, Modiv Industrial's deregistration, Callan JMB's asset acquisition), substantial insider buying at Alibaba ($5M CEO purchase) and 17 Education, contrasted with heavy secondary selling at Aveanna Healthcare. A notable SPAC sector stress is evident, with Roman DBDR facing Nasdaq delisting for low public holders and YHN Acquisition seeking a third extension amid high redemptions. Financial distress signals are flashing at BioXcel Therapeutics, which secured only a one-week debt extension. On the positive side, Aegon expanded its buyback by 150 million euros, and InterCure received a $77 million war damages settlement. Key period-over-period trends from the data show ConnectM Technology's revenue growing 24.2% YoY but with gross margin compression from 36.5% to 28.6%, while Holtec Nuclear's revenue declined 5.8% YoY. The mixed patent verdict for Cytek Biosciences ($56M award) and Sable Offshore's partial legal win create binary event risks. Overall, the filings suggest a market favoring cash returns and defensive positioning, with selective growth in AI-adjacent and rare disease sectors.

19 high priority 31 medium 50 total filings
· daily

Biotech Small-Cap Approvals — August 22, 2026

The August 22, 2026 biotech small-cap approval stream delivered two neutral-signal biosimilar approvals, with zero NME, zero label expansion, and no bullish or bearish signals. Glenmark Pharmaceuticals received approval for fluticasone propionate, a biosimilar entry in the respiratory/inflammatory space, while Sterinova Inc. received the nod for naloxone hydrochloride, a biosimilar targeting opioid overdose reversal. Both approvals are low-conviction, materiality-rated 5/10, with no disclosed peak sales estimates, exclusivity periods, or pricing power data. The key investment takeaway is the absence of high-value NME approvals; these fallback-type entries are incremental for each sponsor but lack the commercial differentiation or catalyst intensity to move sector-level sentiment. Investors should watch for payer contracting dynamics in the naloxone market, where generic erosion could limit Sterinova’s share.

2 total filings
· daily

NME Blockbuster Approvals — August 22, 2026

The digest covers a single FDA approval on August 19, 2026, for an undisclosed drug from Regeneron Pharmaceuticals, Inc. This is categorized as an NME with Priority Review and Orphan Drug designations, generating a bullish signal with high confidence. The approval underscores Regeneron's continued strength in developing targeted therapies for rare diseases, though the lack of disclosed commercial details (peak sales, pricing, market position) limits full investment assessment. The key risk is the absence of specific therapeutic area and indication data, which prevents clustering or competitive analysis. Overall, this event is a positive but opaque signal for Regeneron's pipeline execution.

1 total filings
· daily

Big Pharma Approvals — August 22, 2026

This period contains a single FDA approval: an NME from Regeneron Pharmaceuticals, Inc., designated with Priority Review and Orphan Drug status, representing a high-conviction bullish signal (strength 8/10, materiality 8/10). While the drug name and therapeutic area are not disclosed, the combination of NME, Priority Review, and Orphan designations typically signals a significant unmet medical need with premium pricing potential and 7-year Orphan exclusivity. The absence of any biosimilar or label expansion activity makes this a pure-play NME catalyst for Regeneron, though the lack of commercial details (peak sales, pricing, market position) limits full investment modeling. Key watch items include the drug's launch execution, payer coverage decisions, and any competitive dynamics in the undisclosed indication.

1 total filings
· daily

Orphan Drug Approvals — August 22, 2026

This digest covers a single Orphan Drug Approval on August 22, 2026, from Regeneron Pharmaceuticals. The approval is classified as a fallback type, not an NME, biosimilar, or label expansion, and carries a bullish signal with high materiality. The drug, designated as an NME with Priority Review and Orphan status, targets an undisclosed indication, with no peak sales, exclusivity, or pricing details provided. The key investment takeaway is Regeneron's continued ability to secure expedited FDA designations, signaling strong R&D execution in rare diseases, though the lack of commercial data limits valuation precision. The primary risk is the absence of disclosed market size and competitive positioning, which could obscure revenue potential and IRA exposure.

1 total filings
· daily

New Drug Approvals (Original) — August 22, 2026

During the period of August 22, 2026, the FDA approved three products, comprising zero NMEs, zero biosimilars, and three 'Other' designations. The dominant event is a bullish NME approval for Regeneron Pharmaceuticals, Inc., which received Priority Review and Orphan Drug designations, signaling a high-value, unmet-need asset with strong commercial potential. The remaining two approvals are biosimilar entries for FLUTICASONE PROPIONATE (Glenmark) and NALOXONE HYDROCHLORIDE (Sterinova), both neutral signals reflecting generic competition in established markets. Key risk: the Regeneron NME's indication, peak sales, and pricing power are undisclosed, limiting near-term valuation precision.

3 total filings
· daily

Biotech Small-Cap Approvals — August 21, 2026

The review period from August 14-21, 2026, yielded four generic/biosimilar approvals (FALLBACK type) with no NMEs, no label expansions, and no first-in-class agents. All approvals are classified as neutral signals with equal 5/10 strength and materiality scores, confirming this was a low-catalyst window for biotech small-cap exposure. The approvals cover three distinct therapeutic areas—Parkinson's disease (CARBIDOPA/LEVODOPA via Dr. Reddy's), erectile dysfunction/pulmonary hypertension (TADALAFIL via Jubilant), autoimmune/inflammatory disease (TOFACITINIB via Teva), and oncology (CABOZANTINIB via MSN)—with no dominant therapeutic cluster. The highest-conviction signal is Teva's entry into the JAK inhibitor generic market with TOFACITINIB, exposing Pfizer’s XELJANZ franchise to incremental competition, though XELJANZ already faces multiple generic entrants. The key risk is that none of these approvals advance pipeline quality or signal differentiation, and all are incremental commoditization events with limited near-term commercial disruption given generic saturation in these categories.

4 total filings
· daily

New Drug Approvals (Original) — August 21, 2026

The week of August 14-18, 2026 produced exclusively biosimilar/generic approvals—zero NMEs, zero label expansions, and four 'Fallback' or generic-type drug approvals. The most notable approvals by sponsor include DR REDDYS LABS LTD’s carbidopa/levodopa and TEVA PHARMS USA’s tofacitinib citrate, representing lower-risk, incremental competitive entries. While no novel therapeutic catalysts emerged, the pure biosimilar/generic cadence signals continued erosion pressure on originator franchises in Parkinson’s disease (carbidopa/levodopa), erectile dysfunction (tadalafil), autoimmune therapy (tofacitinib), and oncology (cabozantinib). Key watch items include TEVA’s ability to capture market share against Pfizer’s Xeljanz and genericization dynamics in the kinase inhibitor class. No major bullish signals were identified; all four approvals are neutral for the investing community.

4 total filings
· daily

Federal Construction & Infrastructure Contracts — August 21, 2026

The single contract in this digest, a $149.2 million firm-fixed-price delivery order awarded to HSGS-AMERESCO, LLC by the Department of Veterans Affairs, represents a purely civilian infrastructure play with zero defense exposure. The contract is an energy savings performance contract (ESPC) for VA medical centers, structured as a Service-Disabled Veteran-Owned Small Business set-aside, which limits competitive pressure but also caps scalability. The highest-conviction signal is neutral, reflecting a stable but low-growth revenue stream tied to energy savings verification. Key risks include the fixed-price structure introducing execution risk and the 19-month performance period limiting revenue visibility beyond February 2027.

1 total filings
· daily

VA Healthcare & Services Contracts — August 21, 2026

The sole contract in this digest is a $149.2 million firm-fixed-price delivery order awarded to HSGS-AMERESCO, LLC by the Department of Veterans Affairs for energy savings performance contract (ESPC) work at two VAMCs. This is a purely civilian award with zero defense exposure, reflecting stable VA infrastructure spending but with execution risk tied to energy savings verification. The highest-conviction signal is the SDVOSB set-aside, which limits competition but also caps scalability for the contractor. Key risk is the fixed-price structure, which could compress margins if cost overruns occur during the 19-month performance period.

1 total filings
· daily

HHS & Healthcare Contracts Intelligence — August 21, 2026

This digest covers a single, large HHS contract awarded to the Albert B. Sabin Vaccine Institute, a nonprofit, for Marburg virus R&D under BARDA. The $263.6 million initial obligation is part of a $1.04 billion, 10-year cost-plus-fixed-fee program, representing 100% civilian biodefense spending. The neutral signal (5/10) reflects limited direct equity exposure due to the nonprofit recipient, but the scale and duration underscore sustained government commitment to pandemic preparedness. Key risk is funding uncertainty across a decade-long performance period, with option exercises as critical monitoring points.

1 total filings
· daily

New Federal Contractors — August 21, 2026

The five contracts analyzed, totaling $1.6 billion in obligations, are overwhelmingly civilian (4 of 5), with only one defense-related award. The dominant theme is stable, multi-year IT and infrastructure spending by civilian agencies (GSA, NASA, HHS, VA), with CACI's $674M GSA IT services contract representing the highest-conviction bullish signal due to its cost-plus pricing and competitive win. Key risks include the expired nature of Teledyne Brown's $371M NASA contract (zero future revenue) and the nonprofit status of the Sabin Vaccine Institute's $263M BARDA award, which limits direct equity exposure. Investors should watch for CACI's contract recompete in May 2024 and option exercises on the VA's $149M ESPC award.

5 total filings
· daily

Significant Contract Modifications ($10M+) — August 21, 2026

This digest covers $1.6B in aggregate obligations across 6 contracts, with only 1 of 6 being defense-related (Lockheed Martin's $6K DHS award), making this a heavily civilian-focused period. The dominant theme is federal IT and biodefense spending: CACI's $674M GSA IT services award is the highest-conviction signal, providing predictable cost-plus revenue through 2024. However, the aggregate signal strength is low (4.8/10) due to five neutral-rated contracts, including a $372M NASA ISS support contract from Teledyne Brown that has already expired with only $151M actually outlayed. Key risk: the CACI contract shows a negative net outlay (-$415K), which may indicate accounting adjustments or early-stage execution issues that warrant monitoring.

6 total filings
· daily

Contract Deobligations Alert — August 21, 2026

This digest covers $1.6 billion in total obligations across six contracts, with a striking 5/6 civilian agency split (GSA, NASA, HHS, VA, NIH) and only one defense-related award (DHS, negligible $6K). The dominant theme is stable, multi-year civilian IT and mission support spending, led by a $674M CACI GSA IT services contract (bullish, low-risk cost-plus pricing) and a $371.5M Teledyne NASA ISS support contract (neutral, expired, under-executed). The highest-conviction signal is CACI's competitive win, signaling durable federal IT demand, but the key risk is the Teledyne contract's actual outlays being less than half of obligations, indicating potential execution or funding issues. Overall, the digest points to robust civilian agency IT and biodefense spending, but with limited direct defense exposure and a neutral-to-bullish signal strength averaging 4.8/10.

6 total filings